Navigation Links
Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Apr 16, 2007 - Onconova Therapeutics, Inc. today announced the presentation of several scientific studies relating to its lead anticancer drug ON 01910.Na at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in Los Angeles, California. During this meeting, on Sunday, April 15th, Dr. E. Premkumar Reddy, the scientific founder of Onconova was honored as the recipient of the 2006-2007 Society of Asian American Scientists in Cancer Research Award for his fundamental contributions to cancer research.

Data presented in oral and poster sessions will focus on pre-clinical and clinical studies with ON 01910.Na, a novel, targeted, small-molecule anti-cancer compound undergoing multiple clinical trials at several major clinical centers in the USA and abroad. ON 01910.Na has shown broad-spectrum anti-tumor activity against both solid tumors and hematological malignancy in pre-clinical studies, and has demonstrated synergistic activity when combined with several classes of conventional chemotherapeutic agents. The Company is planning multiple Phase 2 and combination Phase I clinical trials with leading investigators at major oncology clinical centers in the USA.

The antitumor activity of ON 01910.Na in combination with Eloxatin(R) (Sanofi-Aventis) is demonstrated in a poster presentation entitled, "ON 01910.Na enhances the in vivo cancercidal effects of Oxaliplatin" by J. Jiang, Y. Li, L. Wang, J. Qu, P. Mannam, E. P. Reddy and James F. Holland (Mount Sinai School of Medicine, New York). Employing a nude mouse model system and human liver, hormone refractory prostate, melanoma, pancreatic and colon tumors, single agent activity of ON 01910.Na was shown for all tumor types tested and this effect was enhanced by combining with Oxaliplatin in the liver, prostate and melanoma tumor models. ON 01910.Na was well tolerated in all case s, and the combination therapy was as well tolerated as Oxaliplatin treatment alone. This study supports further evaluation of ON 01910.Na and the combination with Oxaliplatin in additional clinical trials in patients with liver, hormone refractory prostate and melanoma tumors (abstract 2271).

An oral presentation, "Phase I study of ON 01910.Na, A Novel Cell Cycle Inhibitor in Adult Patients with Solid Tumors by A. Jimeno, J. Li, M.V.R Reddy, E.P Reddy, A. Chan, X. Zhang, P. Kulesza, J. Wheelhouse, G. Cusatis, A. Howard, M. Maniar, W.A Messersmith, D. Laheru, M. Rudek, S. D. Baker, M. Hidalgo, and R. C. Donehower, summarizes the Phase I study conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Center, Baltimore, MD, in which ON 01910.Na has shown preliminary signs of clinical activity early in development. ON 01910.Na has also evidenced significant preclinical activity against a novel direct pancreatic cancer xenograft model. A gene expression-based assay identifies tumors likely to respond to ON 01910.Na, and will be tested in a Phase II clinical study in pancreatic cancer patients. Integrating early clinical and preclinical development programs is an efficient way to generate rationale for disease-directed studies and biomarkers (oral presentation in a "Breakthroughs in Clinical Research" session on Monday).

Additional scientific studies employing Onconova Therapeutics, Inc., anticancer compounds being presented at this meeting include: "Mass Spectrometric Study of Antibody Drug conjugates" by J. Roboz, S.Y. Cho, S. C. Bell, Glenn J. Fegley, J. L. Duke, S. C. Cosenza and J. F. Holland (abstract 920); "Mass Spectrometric Study of Drug Bound to Protein" by S.Y. Cho, J. Roboz, T. Ohnuma and J. F. Holland (abstract 3182); and "Evaluation of ON 01910.Na, a novel modulator of PLK-1 pathway and development of a cyclin B1 based predictive assay in pancreatic cancer" by A. Jimeno, A. Chan, G. Cusatis, X. Zhang, J. Wheelhouse, A . Solomon, F. Chan, M. Zhao, S. Cosenza, M. Reddy, M. Rudek, P. Kulecza, E. P. Reddy and M. Hidalgo (abstract 5391).

About Onconova's Product-Pipeline

Onconova is developing several novel product candidates directed at critical kinase targets involved in the regulation of signal transduction, cell-cycle and DNA repair. These candidates are derived from the Company's proprietary library of new chemical entities and non-ATP competitive chemotypes. In addition to ON 01910.Na, Onconova is also developing Ex-RAD(TM), an injectable and oral radioprotectant, and inhibitors of JAK and Bcr-abl pathways.

About Onconova Therapeutics, Inc.

Onconova, based in Lawrenceville, NJ, discovers and develops novel therapeutic agents for cancer, radiation protection and hematological disorders. Currently, the Company is conducting clinical trials at major centers in the USA and abroad. The novel chemical library platform is permitting identification of non-ATP competitive kinase inhibitors directed at validated and novel targets, and a new immunoconjugate technology for arming monoclonal antibodies for cancer therapy. All of the Company's products and technologies are being developed internally.

For further information on Onconova Therapeutics, Inc., please visit http://www.onconova.com.

All trademarks are registered to their respective owners.

Contact

Investors
Onconova Therapeutics, Inc.
Dr. Ramesh Kumar
President and CEO
609-844-7735
or
Media
KMorrisPR
Kathryn Morris
845-635-9828
kathryn@kmorrispr.com


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology:
(Date:4/21/2017)... City, Colo. (PRWEB) , ... April 21, 2017 , ... ... of the Flex House, the next project in the company’s esteemed VISION House demonstration ... help homeowners use exactly the amount of resources they need to live affordably and ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University ... printing facility among higher education institutions in Hong Kong to support teaching, learning and ... the range and quantity of facilities in Hong Kong. , With an area ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... Malvern, Worcestershire, UK (PRWEB) , ... April 21, ... ... Queen’s Award for Enterprise in the category of International Trade, the UK’s most ... performance in international trade, which represents 95% of total revenues and has grown ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... BrightStar Care ... partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex Wheeler as ... next chapter of growth for our agency and our ability to provide quality care ...
Breaking Medicine News(10 mins):